Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06211634 · ClinicalTrials.gov registry record · Phase 1
A Phase 1/2 Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Glanzmann Thrombasthenia
A Phase 1 study of Glanzmann Thrombasthenia, sponsored by Hemab ApS.
- Active
- Registry status
- Phase 1
- Development phase
- 57
- Enrollment target
- 17
- Study locations
NCT06211634: Active Phase 1 study of Glanzmann Thrombasthenia, sponsored by Hemab ApS.
NCT06211634 is a Phase 1 study of Glanzmann Thrombasthenia that is active but no longer recruiting, run by Hemab ApS. The registered enrollment target is 57 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. The trial reports 17 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06211634, a Phase 1 study of Glanzmann Thrombasthenia, is active but no longer recruiting, sponsored by Hemab ApS.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 57 participants
- Enrollment target
- 17
- Study locations
Study Summary
The goal of this clinical trial is to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Participants with Glanzmann Thrombasthenia. The main questions it aims to answer are: * Parts A, B, and C: To determine the safety and tolerability of HMB-001 * Part A: To establish the dose level(s) and dosing interval(s) of HMB-001 to be investigated in Parts B and C * Parts B and C: To estimate the ability of HMB-001 to prevent the number and severity of bleeds Part A will assess differing singular doses of HMB-001 in small groups of participants. The dose administered to a newly enrolled participant (or groups of participants) may only increase if analysis of data from previous dosing shows it is safe to do so. The planned duration of participation in Part A is approximately 6 months, which consists of a Screening Period, an optional Run-in Observation Period, and a follow-up period of 8 weeks. Part B is similar to Part A as it involves testing different dose levels of HMB-001 in small groups of participants. However, in Part B, HMB-001 is given multiple times over a 3-month period, either weekly, every 2 weeks, or every 4 weeks. Part B consists of a Screening Period, a Run-in Observation Period, a 3-month Treatment Period, and a Safety Follow-up following the last dose of HMB-001. Part C is open to participants from Part B and consists of approximately a 18-month Treatment Period and a Safety Follow-up following the last dose of HMB-001.
Conditions Studied
Interventions
- DRUG HMB-001
Study Locations (17)
Other
- University Hospital Leuven - Campus Gasthuisberg (Part B/C) - Leuven
- AP-HP Hopital Bicetre (Part B/C) - Le Kremlin-Bicêtre
- AP-HM - Hopital de la Timone - Marseille
- AP-HP Hopital Necker-Enfants Malades (Part B/C) - Paris
- Azienda Ospedaliero-Universitaria Careggi (Part B/C) - Florence
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano (Part B/C) - Milan
- Universitair Medisch Centrum Utrecht (Part B/C) - Utrecht
- Queen Elizabeth Hospital Birmingham (Part B/C) - Birmingham
- Leeds Teaching Hospitals NHS Trust - Leeds
- Richmond Pharmacology Ltd (Part A/B/C) - London
- Royal Free London NHS Foundation Trust (Part B/C) - London
- The Royal London Hospital (Part B/C) - Whitechapel
California
- University of California, San Diego (UCSD) (Part B/C) - La Jolla
Louisiana
- Tulane University Medical Center (Part B/C) - New Orleans
Minnesota
- Mayo Clinic - Rochester (Part B/C) - Rochester
Pennsylvania
- Hemophilia Center of Western Pennsylvania (HCWP) (Part B/C) - Pittsburgh
Washington
- Washington Institute for Coagulation (Part B/C) - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2022-12-13 |
| Est. Completion | 2027-08 |
| Phase | Phase 1 |
What the registry record for NCT06211634 still lists
NCT06211634 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 57 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.
The record links to 1 condition, with Glanzmann Thrombasthenia appearing as the primary indexed condition, and to 1 intervention - of which HMB-001 is the first listed.
NCT06211634 lists 17 locations in 6 states (Other, California, Louisiana).
Frequently Asked Questions
What is clinical trial NCT06211634 about?
NCT06211634 is a clinical study titled "A Phase 1/2 Study to Investigate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Glanzmann Thrombasthenia". The goal of this clinical trial is to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Participants with Glanzmann Thrombasthenia. The main questions it aims to answer are: * Parts A, B, and C: To determine the safety and tolerability of HMB-001 ...
What is the current status of trial NCT06211634?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 57 participants. The study started on 2022-12-13. Estimated completion is 2027-08.
What conditions does trial NCT06211634 study?
This clinical trial studies the following conditions: Glanzmann Thrombasthenia.
What interventions are being tested in trial NCT06211634?
The interventions under investigation include: HMB-001 (DRUG).
Who is sponsoring clinical trial NCT06211634?
This trial is sponsored by Hemab ApS, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06211634 being conducted?
This trial has 17 study locations across California, Louisiana, Minnesota, Pennsylvania, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glanzmann Thrombasthenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06211634's enrollment target sits among peer trials
57 901st of 2000 higher than 1,099 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03521830 · 57 participants · Phase 2
Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
- NCT03587701 · 57 participants · Phase 2
Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease
- NCT04104126 · 57 participants · NA
Blood Flow Restriction Therapy in Achilles Injury
- NCT04703842 · 57 participants · Phase 1
Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI